SIPAI HEALTH(00314.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 43.29 million, turned profitable from a loss YoY
NewTimeSpace News: August 20, 2026, SIPAI HEALTH(00314.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 739.92 million, decreased by 39.55% YoY; Net Profit stood at CNY 42.92 million, turned profitable from a loss YoY; Profit Attributable to Shareholders stood at CNY 43.29 million, turned profitable from a loss YoY; Basic Earnings Per Share (EPS) stood at CNY cents 7.
In terms of profitability, SIPAI HEALTH Gross Profit changed from CNY 176.1 million in the same period last year to CNY 148.53 million in the current period, decreased by CNY 27.57 million; gross profit margin changed from 14.39% in the same period last year to 20.07% in the current period, increased by 5.69 percentage points; net profit changed from loss of CNY 81.14 million in the same period last year to CNY 42.92 million in the current period, increased by CNY 124.06 million; net profit margin changed from -6.63% in the same period last year to 5.8% in the current period, increased by 12.43 percentage points.
In terms of earnings quality, SIPAI HEALTH Operating Profit changed from loss of CNY 81.46 million in the same period last year to CNY 44.12 million in the current period, increased by CNY 125.58 million; Operating Profit Margin changed from -6.66% in the same period last year to 5.96% in the current period, increased by 12.62 percentage points.
In terms of financial soundness, SIPAI HEALTH Debt-to-Asset Ratio changed from 47.81% in the same period last year to 47.16% in the current period, decreased by 0.65 percentage points; Total Equity changed from CNY 956.314 million in the same period last year to CNY 894.958 million in the current period, decreased by CNY 61.36 million; Current Liabilities changed from CNY 865.13 million in the same period last year to CNY 789.1 million in the current period, decreased by CNY 76.03 million; Quick Ratio changed from 1.67 in the same period last year to 1.95 in the current period, increased by 0.28 percentage points.
In terms of R&D investment focus, SIPAI HEALTH R&D Expenses changed from CNY 5.08 million in the same period last year to CNY 5.12 million in the current period, increased by CNY 37 thousand; R&D to Total Revenue Ratio changed from 0.42% in the same period last year to 0.69% in the current period, increased by 0.27 percentage points.
By the close of trading on August 20, 2026, SIPAI HEALTH(00314) saw a gain of 2.4% in its share price, closing at HKD 1.495. The full-day turnover stood at HKD 1.15 million, with the latest market capitalization at HKD 1.09 billion.
NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
